hold
price close busi octob
intuit surgic manufactur da vinci robot
system use wide rang minimally-
biomed devic servic
surg ahead upgrad buy pt
bottom line valuat cheap moder materi latest
market downdraft importantli think robot revolut look prime
continu lead via massiv invest next-gener technolog actual
gain momentum upgrad rate buy increas price target
would accumul share notwithstand expect strength stock
heel robust print
inde surg continu strong underli busi trend continu
across isrg core franchis led global procedur growth acceler
third consecut quarter ww procedur growth growth
impress excit futur name new inject growth
expect begin contribut next sever quarter ramp
updat facilit addit procedur perform robot nascent
geograph opportun japan china upon issuanc new system quota
think augment isrg momentum procedur instal
base total revenu earn growth top isrg compel procedur growth
trend think firm next-gen innov initi name ar/vr informat
advanc imag promulg whole new game robot gener
specif combin firm new tech asset hit market
present sp ion stapler etc act like hall-of-fam closer
playoff basebal game take team solid lead deeper game
command advantag great opportun continu win win share
well expand
procedur volum system growth remain robust global procedur growth
acceler sequenti ww procedur y/i vs
geograph basi us procedur volum grew quarter ou
procedur specif on-going strength us hernia colorect
continu drive domest procedur volum growth uptak bariatr
firm recent stapler launch facilit higher
asp per procedur categori well gener surgeri procedur acceler
quarter growth isrg matur procedur categori dvp dvh remain
solid seemingli expect yet system side isrg ww instal
base grew net basi fuel isrg increasingli flexibl capit
placement option intuit inher focus meet custom demand
real time facilit increas access drive procedur volum growth look
expect moder capit growth come tough
comp also continu strong procedur procedur asp margin trend
three think tantamount investor import
appreci stock
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
sp hit market announc fda clearanc urolog surgic
procedur da vinci sp singl port system earli june firm
commenc measur launch platform three system
ship us market sp near-term impact top line
minim firm focus build clinic data ad addit
indic tor submit recent think sp abil
augment isrg current robot surgeri product portfolio via platform abil
access site natur orific thu expand reach firm
domin robot ecosystem medium term establish
entrench top player robot field sp urolog
indic first step think futur sp indic submiss tor
colorect import busi abil augment
ion flex robot alreadi upon us expans ecosystem flexibl
robot horizon auri hold first-mov advantag us flexibl
robot market follow fda clearanc firm monarch platform march
diagnost therapeut bronchoscop procedur allow
compani initi target lung biopsies/lung cancer diagnosi think
wont far behind market entri front firm recent submit
fda august first potenti indic lung biopsi
ramp post clearanc like slow data key drive adopt
expand beyond current call points/procedur base long-
term opportun inher ion via abil expand addit
indic signific isrg current approach flexibl platform
follow tenet drive isrg iter approach across current
platform name leverag comput assist improv procedur
predict cut oper variabl manag anticip
leverag current infrastructur robot ecosystem ultim captur
share burgeon field flexibl robot quit impress
speed brought ion market think could
portend upsid estim get
stellar japan growth japan recent receiv reimburs
approv addit procedur effect april procedur volum
growth exceed acceler level manag caution
procedur growth next sever quarter could somewhat volatil
new procedur incorpor physician workflow think initi
adopt trend japan portend posit long-term procedur volum
growth region especi given reimburs line laparoscop
level suggest desir perform procedur via robot approach
region strong near-term upsid new market opportun
like remain subdu current system region provid suffici
capac coupl isrg plan control roll-out new procedur
allow adequ train think there lot like around japan
opportun especi give region prefer minim invas
procedur japan provid meaning ramp impact
isrg busi beyond view
china remain hold pattern long-term upsid potenti still
intact china procedur volum growth remain constrain due current
lack new capit quota procedur volum growth region
moder overal ou level continu view china
wildcard upsid driver stori capabl provid anoth leg
growth quota ultim come someth view
buy hold target price octob
biomed devic servic
dynam recent rhetor around tariff trade make form near-
term upsid unlik potenti upsid multipl quarter year
view
guidanc updat base continu procedur volum
strength seen throughout manag rais procedur
volum growth guidanc rang vs recent rang
compar firm initi procedur growth guidanc rang
addit rais lower end pro forma gm
guidanc anticip margin rang vs prior rang
due time associ project plan spend
manag anticip pro forma opex growth rang
level prior rang firm
project incom tax rate rang vs prior rang
model updat revis estim upward updat
model includ estim anticip revenu
previous pro forma ep previous
model revenu previous pro forma
ep previous extend model
anticip revenu pro forma ep princip
upward revis model revenu side stem higher placement
system sale pair increas growth ww procedur gm
improv opex leverag updat price target
appli price-to-earnings multipl pro forma ep previous
util pro forma ep deriv price-to-earnings multipl util
p/e/g y/i growth pro forma ep
buy hold target price octob
biomed devic servic
compani report canaccord genuiti estim past perform predict futur result
figur intuit surgic result vs cg estim consensu project
buy hold target price octob
biomed devic servic
deriv price target appli ratio line large-
cap med-tech comp group ep model forward ep
compound-annual-growth-rate thu aforement target multipl drive target price-to-earnings
appli pro forma ep estim deriv
target
buy hold target price octob
biomed devic servic
p/e/g valuat financi metric use median large-cap medic devic price-to-earnings p/e/g multipl ep pro forma price-to-earnings multipl use group forma price figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy hold target price octob
biomed devic servic
million except per share total servic total gross total oper oper incom expens pre-tax incom tax expens tax incom share ep pro-forma calcul xi trade-in programshar base compens intang liabil litig invest tax net forma ex tax analysisduct adjust sbc ia margin pro margin includ margin pro incom cont figur revenu model
buy hold target price octob
biomed devic servic
total instrument/access total servic total revenu growth modelgrowth rate assumptionsu system unit sale replacements/trad instal base us total total sold ex-oper asp modelgrowth rate procedur growth procedur growth procedur growth gener ou urolog gener gynecolog us ww procedur asp revenue/instal system intuit surgic
